share_log

Ladenburg Thalmann Downgrades Viridian Therapeutics to Neutral

Benzinga ·  May 9 12:14

Ladenburg Thalmann analyst Michael Higgins downgrades Viridian Therapeutics (NASDAQ:VRDN) from Buy to Neutral.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment